Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment

Life Sciences

Volumn 74, Issue 2-3, 2003, Pages 299-311

  Varga, Eva V ^a,b   Yamamura, Henry I ^a,b,c   Rubenzik, Marc K ^a   Stropova, Dagmar ^a   Navratilova, Edita ^a   Roeske, William R ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c University of Arizona   (United States)

Author keywords

Adenylyl cyclase superactivation; Chronic opioid treatment; Excitatory signal transduction; Opioid mediated pain

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ADENYLATE CYCLASE; ADENYLATE CYCLASE ACTIVATOR; CALCITONIN GENE RELATED PEPTIDE; CALMIDAZOLIUM; CALMODULIN DERIVATIVE; CASPASE 3; CHELERYTHRINE; GENISTEIN; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; GW 5074; ISOENZYME; MORPHINE; NALTRINDOLE; OPIATE; OPIATE RECEPTOR; PERTUSSIS TOXIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; PROTEIN KINASE; RAF PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; SUBSTANCE P; UNCLASSIFIED DRUG;

ALLODYNIA; APOPTOSIS; CATALYST; CELL REGENERATION; CELL STRAIN COS7; CELLULAR DISTRIBUTION; CHO CELL; CONFERENCE PAPER; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME BINDING; FIBROBLAST; GLIOMA CELL; HYBRID CELL; HYPERALGESIA; LONG TERM CARE; MOLECULAR MECHANICS; MYENTERIC PLEXUS; NERVE CELL PLASTICITY; NEUROBLASTOMA CELL; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN; PAIN THRESHOLD; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; RECEPTOR SENSITIVITY; SIGNAL TRANSDUCTION;

CRICETINAE; CRICETULUS GRISEUS;

EID: 0242289614     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.09.017     Document Type: Conference Paper

References (78)

1. Ammer H., Schulz R. Chronic activation of inhibitory δ-opioid receptors cross-regulates the stimulatory adenylyl cyclase-coupled prostaglandin E1 receptor system in NG108-15 hybrid cells. Journal of Neurochemistry. 64:1995;2449-2456.
2. sα. Molecular Pharmacology. 52:1997;993-999.
3. Ammer H., Schulz R. Chronic morphine treatment increases stimulatory beta-2 adrenoreceptor signaling in A431 cells stably expressing the mu opioid receptor. Journal of Pharmacology and Experimental Therapeutics. 280:1997;512-520.
4. Ammer H., Schulz R. Adenylyl cyclase supersensitivity in opioid-withdrawn NG108-15 hybrid cells requires Gs but is not mediated by the Gsalpha subunit. Journal of Pharmacology and Experimental Therapeutics. 286:1998;855-862.
5. Avidor-Reiss T., Nevo I., Levy R., Pfeuffer T., Vogel Z. Chronic opioid treatment induces adenylyl cyclase V superactivation. Journal of Biological Chemistry. 271:1996;21309-21315.
6. Avidor-Reiss T., Nevo I., Saya D., Bayewitz M., Vogel Z. Opiate-induced adenylyl cyclase superactivation is isoenzyme-specific. Journal of Biological Chemistry. 272:1997;5040-5047.
7. Basbaum A.I., Fields H.L. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annual Reviews in Neuroscience. 7:1984;309-338.
8. Bayewitz M.L., Nevo I., Avidor-Reiss T., Levy R., Simmonds W.F., Vogel Z. Alterations in detergent solubility of heterotrimeric G proteins after chronic activation of Gi/o-coupled receptors: Changes in detergent solubility are in correlation with onset of adenylyl cyclase superactivation. Molecular Pharmacology. 57:2000;820-825.
9. Belcheva M.M., Coscia C.J. Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase. Neurosignals. 11:2002;34-44.
10. Belcheva M.M., Szucs M., Wang D., Sadee W., Coscia C.J. Mu opioid receptor-mediated ERK activation involves calmodulin dependent EGF receptor transactivation. Journal of Biological Chemistry. 276:2001;33847-33853.
11. Cahill C.M., Morinville A., Lee M.C., Vincent J.P., Collier B., Beaudet A. Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. Journal of Neuroscience. 21:2001;7598-7607.
12. Carruthers A.M., Sellers L.A., Jenkins D.W., Jarvie E.M., Feniuk W., Humphrey P.P. Adenosine A(1) receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons. Molecular Pharmacology. 59:2001;1533-1541.
13. Celerier E., Laulin J.P., Corcuff J.B., Le Moal M., Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. Journal of Neuroscience. 21:2001;4074-4080.
14. Chakrabarti S., Wang L., Tang W.-J., Ginzler A.R. Chronic morphine augments adenylyl cyclase phosphorylation: Relevance to altered signaling during tolerance/dependence. Molecular Pharmacology. 54:1998;949-953.
15. Charles A.C., Mostovskaya N., Asas K., Evans C.J., Dankovich M.L., Hales T.G. Coexpression of delta-opioid receptors with μ receptors in GH3 cells changes the functional response to μ agonists from inhibitory to excitatory. Molecular Pharmacology. 63:2003;89-95.
16. + channels on amygdala neurons of morphine-dependent rats. Proceedings of the National Academy of Sciences U.S.A. 97:2000;14692-14696.
17. Chieng B., Christie M.J. Local opioid withdrawal in rat single periaqueductal gray neurons in vitro. Journal of Neuroscience. 16:1996;7128-7136.
18. Connor M., Borgland S.L., Christie M.J. Continued morphine modulation of calcium channel currents in acutely isolated locus coeruleus neurons from morphine-dependent rats. British Journal of Pharmacology. 128:1999;1561-1569.
19. Crain S.M., Shen K.F. After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside. Brain Research. 575:1992;13-24.
20. Crain S.M., Shen K.F. Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends in Pharmacological Sciences. 19:1998;358-365.
21. DeVries T.J., Schippenberg T.S. Neural systems underlying opiate addiction. Journal of Neuroscience. 22:2002;3321-3325.
22. 2+-, and calmodulin. Molecular Cellular Biology. 20:2000;1931-1946.
23. Eisinger D.A., Ammer H., Schulz R. Chronic morphine treatment inhibits opioid receptor desensitization and internalization. Journal of Neuroscience. 22:2002;10192-10200.
24. Fan G.H., Wang L.Z., Qiu H.C., Ma L., Pei G. Inhibition of calcium/calmodulin-dependent protein kinase II in rat hippocampus attenuates morphine tolerance and dependence. Molecular Pharmacology. 56:1999;39-45.
25. Fleming W.W., Taylor D.A. Cellular mechanisms of opioid tolerance and dependence. Tseng L. The Pharmacology of Opioid Peptides. 1995;463-502 Harvard Academic Publishers.
26. Fry J.P., Zieglgansberger W., Herz A. Development of acute opioid tolerance and dependence in rat striatal neurones. Naunyn Schmiedebergs Archives fur Pharmacologie. 313:1980;145-149.
27. Fukuda K., Kato S., Morikawa H., Shoda T., Mori K. Functional coupling of δ, μ, and κ-opioid receptors to MAP kinase and arachidonate release in Chinese hamster ovary cells. Journal of Neurochemistry. 67:1996;1309-1316.
28. Ingram S.L., Vaughan C.W., Bagley E.E., Connor M., Christie M.J. Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. Journal of Neuroscience. 18:1998;10269-10276.
29. Ikeda K., Kobayashi T., Kumanishi T., Yano R., Sora I., Niki H. Molecular mechanisms of analgesia induced by opioids and ethanol: is the GIRK channel one of the keys? Neuroscience Research. 44:2002;121-131.
30. Ishikawa Y. Regulation of cAMP signaling by phosporylation. Advances in Second Messenger Phosphoprotein Research. 32:1998;99-120.
31. Jhamandas K.H., Marsala M., Ibuki T., Yaksh T.L. Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine. Journal of Neuroscience. 16:1996;2758-2766.
32. Jin W., Lee N.M., Loh H.H., Thayer S.A. Opioid mobilize calcium from inositol 1,4,5-triphosphate-sensitive stores in NG108-15 cells. Journal of Neuroscience. 14:1994;1920-1929.
33. Jordan B.A., Cvejic S., Devi L.A. Opioids and their complicated receptor complexes. Neuropsychopharmacology. 23:2000;S5-S18.
34. Law P.-Y., Loh H.H. Delta opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma×glioma NG108-15 hybrid cells. Molecular Pharmacology. 43:1993;684-693.
35. Liu J.G., Prather P.L. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Molecular Pharmacology. 60:2001;53-62.
36. Liu J.G., Prather P.L. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors. Journal of Pharmacology and Experimental Therapeutics. 302:2002;1070-1079.
37. Lou L., Zhou T., Wang P., Pei G. Modulation of Ca2+/calmodulin-dependent protein kinase II activity by acute and chronic administration in rat hippocampus. Molecular Pharmacology. 55:1999;557-563.
38. Malatynska E., Wang Y., Knapp R.J., Waite S., Calderon S., Rice K.C., Hruby V.J., Yamamura H.I., Roeske W.R. Human delta opioid receptor: Functional studies on stably transfected CHO cells following acute and chronic treatment with the selective non-peptidic agonist SNC-80. Journal of Pharmacology and Experimental Therapeutics. 278:1996;1083-1089.
39. Mao J., Price D.D., Mayer D.J. Thermal hyperalgesia in association with the development of morphine tolerance in rats. Journal of Neuroscience. 14:1994;2301-2312.
40. Mao J., Price D.D., Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance: Current view of their possible interaction. Pain. 62:1995;259-274.
41. Mao J., Sung B., Ji R.-R., Lim G. Neuronal apoptosis associated with morphine tolerance: Evidence for an opioid-induced neurotoxic mechanism. Journal of Neuroscience. 22:2002;7650-7661.
42. Mayer D.J., Mao J., Holt J., Price D.D. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proceedings of the Naional Academy of Sciences U.S.A. 96:1999;7731-7736.
43. Moreau J.L., Fields H.L. Evidence for GABA involvement in midbrain control of medullary neurons that modulate nociceptive transmission. Brain Research. 397:1986;37-46.
44. Narita M., Ioka M., Suzuki M., Narita M., Suzuki T. Effect of repeated administration of morphine on the activity of extracellular signal regulated kinase in the mouse brain. Neuroscience Letters. 324:2002;97-100.
45. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nature Reviews, Neuroscience. 2:2001;119-128.
46. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science. 278:1997;58-63.
47. Olianas M.C., Onali P. Mediation by G protein beta-gamma-subunits of the opioid stimulation of adenylyl cyclase activity in rat olfactory bulb. Biochemical Pharmacology. 57:1999;649-652.
48. Ostermeier A.M., Schlosser B., Schwender D., Sutor B. Activation of mu- and delta-opioid receptors causes presynaptic inhibition of glutamatergic excitation in neocortical neurons. Anesthesiology. 93:2000;1053-1063.
49. Quock R.M., Burkey T.H., Varga E.V., Hosohata Y., Hosohata K., Cowell S.M., Slate C.A., Ehlert F.J., Roeske W.R., Yamamura H.I. The δ-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacological Reviews. 51:1999;503-531.
50. Rivera M., Ginzler A.R. Differential effect of chronic morphine on mRNA encoding adenylyl cyclase isoforms: relevance to physiological sequela of tolerance/dependence. Molecular Brain Research. 54:1998;165-169.
51. Rubenzik M., Varga E.V., Stropova D., Roeske W.R., Yamamura H.I. Expression of α-transducin in Chinese hamster ovary cells stably transfected with the human δ-opioid receptor attenuates agonist-induced adenylyl cyclase superactivation. Molecular Pharmacology. 60:2001;1076-1082.
52. Russell J.A., Leng G., Bicknell R.J. Opioid tolerance and dependence in the magnocellular oxytocin system: a physiological mechanism? Experimental Physiology. 80:1995;307-340.
53. i- and Protein kinase C mediated heterologous potentiation of phospholipase C signaling by G-protein coupled receptors. Molecular Pharmacology. 53:1998;1139-1148.
54. Schmidt H., Schulz S., Klutzny M., Koch T., Handel M., Hollt V. Involvement of mitogen-activated protein kinase in agonist-induced phosphorylation of the mu-opioid receptor in HEK 293 cells. Journal of Neurochemistry. 74:2000;414-422.
55. Sharma S.K., Klee W.A., Nirenberg M. Dual regulation of adenylyl cyclase accounts for narcotic dependence and tolerance. Proceedings of the National Academy of Sciences U.S.A. 72:1975;3092-3096.
56. Shen K.F., Crain S.M. Cholera toxin B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesis and attenuating opioid tolerance/dependence. Brain Research. 919:2001;20-30.
57. Smart D., Lambert D.G. The stimulatory effects of opioids and their possible role in the development of tolerance. Trends in Pharmacological Sciences. 17:1996;264-269.
58. Smart D., Lambert D.G. δ-opioids stimulate inositol 1,4,5-triphosphate formation, and so mobilize calcium from intracellular stores, in undifferentiated NG108-15 cells. Journal of Neurochemistry. 66:1996;1462-1467.
59. Tan C.M., Kelvin D.J., Litchfield D.W., Ferguson S.S.G., Feldman R.D. Tyrosine kinase-mediated serine phosphorylation of adenylyl cyclase. Biochemistry. 40:2001;1702-1709.
60. Taylor D.A., Fleming W.W. Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. Journal of Pharmacology and Experimental Therapeutics. 297:2001;11-18.
61. Thomas J.M., Hoffman B.B. Adenylate cyclase supersensitivity: a general means of cellular adaptation to inhibitory agonists? Trends in Pharmacological Sciences. 8:1987;308-311.
62. Trang T., Sutak M., Quirion R., Jhamandas K. The role of spinal neuropeptides and prostaglandins in opioid physical dependence. British Journal of Pharmacology. 136:2002;37-48.
63. Xin L., Geller E.B., Liu-Chen L.Y., Chen C., Adler M.W. Substance P release in the rat periaqueductal gray and preoptic anterior hypothalamus after noxious cold stimulation: effect of selective mu and kappa opioid agonists. Journal of Pharmacology and Experimental Therapeutics. 282:1997;1055-1063.
64. Yaksh T.L., Jessell T.M., Gamse R., Mudge A.W., Leeman S.E. Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature. 286:1980;155-157.
65. Yaksh T.L., Harty G.J., Onofrio B.M. High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology. 64:1986;590-597.
66. Yaksh T.L. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiologica Scandinavica. 41:1997;94-111.
67. Vanderah T.W., Gardell L.R., Burgess S.E., Ibrahim M., Dogrul A., Zhong C.M., Zhang E.T., Malan T.P. Jr., Ossipov M.H., Lai J., Porreca F. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. Journal of Neuroscience. 20:2000;7074-7079.
68. Vanderah T.W., Ossipov M.H., Lai J., Malan T.P., Porreca F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain. 92:2001;5-9.
69. Vanderah T.W., Suenaga N.M., Ossipov M.H., Malan T.P. Jr., Lai J., Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. Journal of Neuroscience. 21:2001;279-286.
70. Varga E.V., Stropova D., Rubenzik M., Wang M., Landsman R.S., Roeske W.R., Yamamura H.I. Identification of adenylyl cyclase isoenzymes in CHO and B82 cells. European Journal of Pharmacology. 348:1998;R1-R2.
71. Varga E.V., Stropova D., Rubenzik M., Waite S., Roeske W.R., Yamamura H.I. Phosphorylation of adenylyl cyclase VI upon chronic δ-opioid receptor stimulation. European Journal of Pharmacology. 364:1999;R1-R2.
72. Varga E.V., Rubenzik M., Grife V., Sugiyama M., Stropova D., Roeske W.R., Yamamura H.I. Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation. European Journal of Pharmacology. 451:2002;101-103.
73. Varga E.V., Rubenzik M.K., Stropova D., Sugiyama M., Grife V., Hruby V.J., Rice K.C., Roeske W.R., Yamamura H.I. Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic delta-opioid agonist treatment. Journal of Pharmacology and Experimental Therapeutics. 306:2003;109-115.
74. Varga E.V. The molecular mechanisms of cellular tolerance to δ-opioid agonists. Acta Biologica Hungarica. 54:2003;203-218.
75. Vaughan C.W., Ingram S.L., Connor M.A., Christie M.J. How opioids inhibit GABA-mediated neurotransmission. Nature. 390:1997;611-614.
76. Wang Z., Bilsky E.J., Porreca F., Sadee W. Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sciences. 54:1994;PL339-PL350.
77. Wang D., Sadee W., Quillan J.M. Calmodulin binding to G protein coupling domain of opioid receptors. Journal of Biological Chemistry. 274:1999;22081-22088.
78. Williams J.T., Christie M.J., Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiological Reviews. 81:2001;299-343.